申请人:RIKEN
公开号:EP4066896A1
公开(公告)日:2022-10-05
A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).
一种由下列通式(I)表示的化合物或其药理学上可接受的盐已被发现具有强烈的G9a抑制作用。该化合物(I)或其药理学上可接受的盐抑制G9a,因此在治疗、预防或抑制各种病理状况(如增殖性疾病,如癌症,β-珠蛋白异常,纤维化,疼痛,神经退行性疾病,普拉德-威利综合症,疟疾,病毒感染,肌肉病,自闭症等)方面具有高度的有用性。